Alcon reports Systane study result for Alcon stock

Published on 10/29/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A 256-patient Systane study met its goal at two checkpoints. The evidence adds a new clinical data point for Alcon stock before results.

Systane evidence expands

Alcon reported non-inferior Systane PRO PF results on October 2, 2026.
The randomized study included 256 patients and assessed outcomes at two weeks and one month.
The trial used a prespecified non-inferiority margin of 7.3 OSDI units.
The findings were presented at the American Academy of Optometry meeting from September 30 to October 3, 2026.

Alcon Inc., CH0432492467, Illustration mit AI erstellt.

Alcon (ISIN CH0432492467) reported new clinical evidence for SYSTANE PRO Preservative-Free on October 2, 2026. In a prospective, randomized study of 256 patients with moderate-to-severe dry-eye symptoms, the treatment met the prespecified non-inferiority endpoint against perfluorohexyloctane at two weeks and one month, according to Alcon.

Study design gives the result weight

The head-to-head trial compared SYSTANE PRO PF with perfluorohexyloctane, the active ingredient in MIEBO, using Ocular Surface Disease Index scores. Alcon said the prespecified non-inferiority margin was 7.3 OSDI units, while the between-group differences were minus 2.7 at two weeks and minus 3.0 at one month.

Both treatment groups achieved statistically significant and clinically meaningful reductions in symptoms, with p-values of 0.001 or lower, and the improvement continued through one month. The study was double-masked and multicenter, which gives the result a clearer clinical frame than a simple product survey.

Commercial relevance comes next

SYSTANE PRO PF is sold over the counter in the United States, Canada and other markets, while MIEBO is prescription-only in the United States. That distribution distinction gives Alcon a practical access angle, although the release reports clinical comparability rather than a sales forecast.

The data were presented at the American Academy of Optometry 2026 Annual Meeting, held from September 30 to October 3, 2026. For Alcon stock, the study adds a fresh operating datapoint alongside the companys Surgical and Vision Care businesses.

Next evidence point

Alcon is scheduled to report third-quarter results on November 10, 2026, according to the companys investor-relations calendar. That report will provide the next dated test of revenue, earnings and commercial execution.

The further course of trading is shown by the continuously updated real-time quote of Alcon stock.